• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Burow Kristina

    5/22/25 7:39:32 PM ET
    $MTSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTSR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Burow Kristina

    (Last) (First) (Middle)
    C/O METSERA, INC. 3 WORLD TRADE CENTER
    175 GREENWICH STREET

    (Street)
    NEW YORK NY 10007

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Metsera, Inc. [ MTSR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $29.25 05/20/2025 A 16,125 (1) 05/19/2035 Common Stock 16,125 $0 16,125 D
    Explanation of Responses:
    1. The options will vest and become exercisable in 12 substantially equal monthly installments after the date of grant, such that the option will be vested in full on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.
    Remarks:
    Exhibit List - Exhibit 24 - Power of Attorney
    /s/ Matthew Lang, Attorney-in-fact for Kristina Burow 05/22/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MTSR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTSR

    DatePrice TargetRatingAnalyst
    2/25/2025$56.00Buy
    Guggenheim
    2/25/2025$38.00Buy
    BofA Securities
    2/25/2025Outperform
    Evercore ISI
    More analyst ratings

    $MTSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Metsera with a new price target

      Guggenheim initiated coverage of Metsera with a rating of Buy and set a new price target of $56.00

      2/25/25 7:57:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Metsera with a new price target

      BofA Securities initiated coverage of Metsera with a rating of Buy and set a new price target of $38.00

      2/25/25 7:56:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evercore ISI initiated coverage on Metsera

      Evercore ISI initiated coverage of Metsera with a rating of Outperform

      2/25/25 7:56:13 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    SEC Filings

    See more
    • SEC Form 8-K filed by Metsera Inc.

      8-K - Metsera, Inc. (0002040807) (Filer)

      6/9/25 7:04:25 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Metsera Inc.

      SCHEDULE 13G - Metsera, Inc. (0002040807) (Subject)

      6/3/25 4:30:15 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Metsera Inc.

      SCHEDULE 13G/A - Metsera, Inc. (0002040807) (Subject)

      5/12/25 10:36:17 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Burow Kristina converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:15:35 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Berns Paul L bought $14,219,964 worth of shares (789,998 units at $18.00) and converted options into 7,523,682 shares (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:04:05 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Arch Venture Partners Xii, Llc converted options into 23,530,631 shares and bought $39,999,996 worth of shares (2,222,222 units at $18.00) (SEC Form 4)

      4 - Metsera, Inc. (0002040807) (Issuer)

      2/3/25 7:01:33 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Pinto Joshua

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:42:42 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Executive Chairman Meanwell Clive

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:40:27 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Burow Kristina

      4 - Metsera, Inc. (0002040807) (Issuer)

      5/22/25 7:39:32 PM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Financials

    Live finance-specific insights

    See more
    • Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

      Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

      6/9/25 7:00:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MTSR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR) ("Metsera" or the "Company"), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced that Whit Bernard, its Chief Executive Officer, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11 at 10:00 – 10:35 A.M. EDT. A live webcast and replay of the presentation will be available on the Events page in the Investors & News section of the Metsera website at investors.metsera.com. About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines

      6/10/25 7:00:39 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i

      Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host conference call and webcast today at 8:00 A.M. ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), today announced positive topline data from the Phase 1 clinical trial of MET-233i, an ultra-long acting amylin analog engineered for class-leading durability, potency, and combinability with Metsera's fully-biased monthly GLP-1 receptor agonist candidate, MET-097i. In the study, MET-233i demonstrated up to 8.4% mean placeb

      6/9/25 7:00:00 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®

      Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets, including MET-233i, a monthly, ultra-long acting amylin analog NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (NASDAQ:MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, will highlight the breadth and momentum of its portfolio of ultra-long acting, scalable, and combinable therapies, including updated clinical and preclinical findings from lead program MET-097i, at the 85th Scientif

      6/5/25 7:30:18 AM ET
      $MTSR
      Biotechnology: Pharmaceutical Preparations
      Health Care